Reproductive Biotechnology Research Center, Avicenna Research Institute (ARI), ACECR, Tehran, Iran.
Department of Obstetrics and Gynecology, IVF Clinic, Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
J Reprod Immunol. 2021 Nov;148:103427. doi: 10.1016/j.jri.2021.103427. Epub 2021 Sep 21.
To overcome COVID-19 long-term consequences, one possible approach is to control inflammasomes activation, because SARS-CoV-2 can induce humoral and cellular immune responses. In this opinion article we hypothesized that if it is proven with convincing and unmistakable evidence that firstly, SARS-CoV-2 can enter cells and damage them through its common receptors in the reproductive tissues, and secondly, inflammasome pathway activation is responsible for the damages caused, then the inflammasome inhibitors might be considered as suitable candidates in preventing the pathological effects on the germ cells and reproductive tissues and subsequent fertility.
为了克服 COVID-19 的长期后果，一种可能的方法是控制炎症小体的激活，因为 SARS-CoV-2 可以诱导体液和细胞免疫反应。在这篇观点文章中，我们假设如果有令人信服和无可置疑的证据证明，首先，SARS-CoV-2 可以通过其在生殖组织中的常见受体进入细胞并对其造成损害，其次，炎症小体途径的激活是造成损害的原因，那么炎症小体抑制剂可能被认为是预防生殖细胞和生殖组织的病理影响以及随后的生育能力下降的合适候选药物。
